About Imperagen
Imperagen is a company based in Manchester (United Kingdom) founded in 2021 by Timothy Eyes, Andrew Almond, and Andrew Currin. Imperagen has raised $4.28 million across 1 funding round from investors including Northern Gritstone and IQ Capital. Imperagen offers products and services including Digital Enzyme Evolution Platform and AI-powered Hotspot Identification. Imperagen operates in a competitive market with competitors including ZYMVOL, Nanosyn and DirectBio, among others.
- Headquarter Manchester, United Kingdom
- Founders Timothy Eyes, Andrew Almond, Andrew Currin
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Imperagen
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.28 M (USD)
in 1 rounds
-
Latest Funding Round
$4.28 M (USD), Seed
Aug 02, 2022
-
Investors
Northern Gritstone
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Imperagen
Imperagen offers a comprehensive portfolio of products and services, including Digital Enzyme Evolution Platform and AI-powered Hotspot Identification.
AI and automation platform accelerates enzyme development for performance improvements.
Identifies key enzyme parts using algorithms for faster experimental predictions.
Funding Insights of Imperagen
Imperagen has successfully raised a total of $4.28M through 1 strategic funding round. The most recent funding activity was a Seed round of $4.28 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Imperagen
Imperagen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Northern Gritstone and IQ Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focused on investing in science and technology firms
|
Locked | Locked | Locked | |
|
Deep tech venture capital firm investing in European and global startups.
|
Locked | Locked | Locked |
Investor details for Imperagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Imperagen
Investment portfolio details for Imperagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Imperagen
Detailed financials for Imperagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imperagen Comparisons
Peer comparison for Imperagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Imperagen
Imperagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ZYMVOL, Nanosyn and DirectBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of enzyme development & designing, biocatalysis, and protein engineering services
|
|
| Locked | Locked | Locked |
Preclinical CRO services in chemistry and biological assays are offered.
|
|
| Locked | Locked | Locked |
Pioneers CRISPR-based tools for accurate airborne virus monitoring in various settings.
|
Detailed competitors of Imperagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imperagen
Complete news archive for Imperagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Imperagen
Imperagen was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Imperagen is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Andrew Almond is the current CEO of Imperagen. They have also founded this company.
Imperagen is a funded company, having raised a total of $4.28M across 1 funding round to date.
Imperagen was founded in 2021 in Manchester, United Kingdom, within the biotechnology sector. An enzyme engineering platform is utilized by the company to advance drug development processes. Enzyme products are provided for manufacturing complex drug molecules. Operations extend to laboratory tools, enzyme replacement therapies, and drug delivery systems, supporting various pharmaceutical applications in the region.
Imperagen offers Digital Enzyme Evolution Platform and AI-powered Hotspot Identification.
Imperagen has 2 investors. Key investors include Northern Gritstone, and IQ Capital.